Keywords
Type 2 diabetes mellitus
Glycemic control
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the approach of glycemic control in patients with heart failure and type 2 diabetes mellitus. Methods: This is an integrative review in the databases of Latin American and Caribbean Literature (LILACS) and PubMed, taking into consideration the scientific production from 2028 to 2023. The following descriptors were used: "heart failure; Type 2 diabetes mellitus; glycated hemoglobin; adults; heart disease". Results: The final sample consisted of 05 (five) articles, which indicated that strict glycemic control may be associated with worse cardiovascular outcomes. The range of glycated hemoglobin around 7% was associated with fewer unfavorable events. Sodium-glucose cotransporter inhibitors demonstrated efficacy in reducing cardiovascular morbidity and mortality in patients with heart failure. Final considerations: Glycemic control has been shown to be an important parameter in reducing cardiovascular death and hospitalization. The choice of antidiabetic therapy is of great importance and should target cardioprotective effects for heart failure. However, there is still a scarcity of studies in this area and further research is needed for a better understanding of aspects that have not been clearly outlined.
References
AMIEL SA, et al. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. The lancet Diabetes & endocrinology, 2019; 7(5): 385-396.
BRASIL. Ministério da Saúde. Estratégia de Saúde Cardiovascular: instrutivo para profissionais e gestores da Atenção Primária à Saúde. 2022. Disponível em: https://www.aps.saude.gov.br. Acessado em: 13 de novembro de 2022.
DUNLAY SM, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation, 2019; 140(7): e294.
FEDERAÇÃO INTERNACIONAL DE DIABETES. Atlas de Diabetes da IDF, 9ª edição, 2019. Acessado em 14 de novembro de 2023. Disponível em: https://www.diabetesatlas.org. Acessado em: 13 de novembro de 2022.
FITCHETT D, et al. Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial. European Heart Journal, 2020; 41(2): 209-217.
INZUCCHI SE, et al. Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial. The Journal of Clinical Endocrinology & Metabolism, 2020; 105(9): 3025-3035.
JIA G, et al. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circulation research, 2018; 122(4): 624-638.
JÜRGENS M et al. Effects of empagliflozin on myocardial flow reserve in patients with type 2 diabetes mellitus: the SIMPLE study. Journal of the American Heart Association, 2021; 15: e-020418.
KENNY HC e ABEL E. Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies and new therapeutic strategies. Circulation research, 2019; 124(1): 121-141.
LONG C, et al. Association of long-term visit-to-visit variability of HbA1c and fasting glycemia with hypoglycemia in type 2 diabetes mellitus. Frontiers in endocrinology, 2022; 13: e-975468.
MARX N, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). European Heart J, 2023; 44(39): 4043-4140.
MCALISTER, FA. et al. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. European journal of heart failure, 2020; 22(11), 2026-2034.
MONTVIDA O, et al. Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care 2018; 41: 69–78.
PALAZZUOLI A e IACOVIELLO M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Failure Reviews, 2023; 28(3): 585-596.
PEDROSA HC, et al. Diretrizes Sociedade Brasileira de Diabetes 2019-2020. 2019.
PETRIE MC, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. Jama, 2020; 323(14): 1353-1368.
QUINAGLIA T, et al. Diabetic cardiomyopathy: factual or factoid?. Revista da Associação Médica Brasileira, 2019; 65: 61-69.
SEFEROVIĆ PM, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European journal of heart failure, 2018; 20(5): 853-872.
SEGAR MW, et al. Association of long-term change and variability in glycemia with risk of incident heart failure among patients with type 2 diabetes: a secondary analysis of the ACCORD trial. Diabetes Care, 2020; 43(8): 1920-1928.
WANG MT, et al. Association between specificity of sulfonylureas to cardiac mitochondrial KATP channels and the risk of major adverse cardiovascular events in type 2 diabetes. Diabetes Care, 2022; 45(5): 1276-1287.
ZAVERI MP, et al. Diabetic cardiomyopathy as a clinical entity: is it a myth? Cureus, 2020; 12(10).